Other income buoys Glaxo India's net profit - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Other income buoys Glaxo India's net profit

Apr 25, 2000

Glaxo India has reported only a 7.3% growth in topline in line with the trends in the domestic pharmaceutical sector. Operating margins have crashed from 10% in the first quarter of last year to 6% in the current quarter. The net profit has grown primarily because of the doubling of the other income. The company at the last analysts meet had indicated that while the property sales at Chennai and Delhi had been concluded last year, it could restructure its brand portfolio in the current year. This would involve the sales of its older tail end brands, consolidation in areas such as antibiotics and dermatologicals and introduce new products in respiratory segments. However, the company has not clarified about the source of its other income.

The stock price has mirrored the trend in fundamentals and knocked of almost 50% of its price over the last six months.

(Rs m) FY1999 FY2000 Change
Sales 1,707 1,832 7.3%
Other Income 80 167 108.6%
Expenditure 1,535 1,725 12.4%
Operating Profit (EBDIT) 173 107 -37.8%
Operating Profit Margin (%) 10% 6%  
Interest 17 21 21.6%
Depreciation 36 39 10.4%
Profit before Tax 200 214 7.0%
Other Adjustments      
Tax 67 73 9.3%
Profit after Tax/(Loss) 133 141 5.9%
Net profit margin (%) 7.8% 7.7%  

Equitymaster requests your view! Post a comment on "Other income buoys Glaxo India's net profit". Click here!


More Views on News

GSK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

Here's an analysis of the annual report of GSK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 1, 2021 (Close)


  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks